Article -> Article Details

Increasing prevalence of traumatic brain injuries (TBI) caused by accidents is one of the major factors driving market growth. Posttraumatic hydrocephalus is a condition caused in the aftermath of BTI which can use blockage in ventricles of the brain leading to excess levels of cerebrospinal fluid (CSF). Investments in development of new shunts which can expedite the draining of CSF are likely to spur market growth.

The global hydrocephalus market size is estimated to balloon to USD 1,752.07 million by 2023, asserts Market Research Future (MRFR). It can exhibit 4.4% CAGR over the forecast period (2018-2023). It was previously valued at USD 1,348 million in 2017. High incidence of traumatic brain injuries owing to accidents is the primary driver of the market.

Emergence of various neurovascular diseases such as arteriovenous malformations (AVMs) and brain aneurysm is predicted to bolster the hydrocephalus market growth. This can be attributed to the uptick of neurological conditions witnessed in Asia Pacific. Favorable reimbursement schemes which cover treatment costs coupled with the large patient pool are other factors which can foster growth.

Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1719 

Although high procedural costs of intracranial pressure (ICP) monitoring devices and lack of skilled professionals remain growth deterrents.

Competitive Analysis:

Major industry leaders in the hydrocephalus market are B. Braun Melsungen AG (Germany), Sophysa SA (France), Spiegelberg GmbH & Co. KG (Germany), Terumo Corporation (U.S.), DePuy Synthes (U.S.), Integra LifeSciences Corporation (U.S.), Medtronic Plc (Ireland), Tokibo Co., Ltd. (Japan), Natus Medical Incorporated (U.S.), Boston Neurosciences (U.S.), HLL Lifecare Limited (India), Christoph Miethke GmbH & Co. KG (Germany), Johnson & Johnson Services Inc. (U.S.), and RAUMEDIC Inc. (Germany).

Segmentation Analysis:

The hydrocephalus market is segmented by type, diagnosis, treatment, and end-user.

• By Type, congenital hydrocephalus held 36% share in 2017, followed by acquired hydrocephalus (31%), normal-pressure hydrocephalus (19%), and ex-vacuo hydrocephalus (14%). Congenital hydrocephalus led the hydrocephalus market owing to 55% of hydrocephalus cases turn out to be due to genetic factors. The segment can exhibit 3.65% CAGR over the forecast period to touch a value of USD 601.93 million by 2023. But the normal-pressure hydrocephalus segment can exhibit the highest CAGR of 4.92% during the assessment period to reach a size of USD 345.07 million by 2023.
• By Diagnosis, MRI can display 4.93% CAGR during the assessment period to reach a value of USD 659.86 million by 2023. This can be attributed to the effectiveness of MRI technology to scan malformations in the brain. On the other hand, the CT scan-head segment can display 3.86% CAGR to accrue USD 756.21 million by 2023. The application of the technology to gain the presence of the condition at an early stage in adults and infants can drive its growth.
• By Treatment, surgery-shunt insertion accounted for 59% market share in 2017, followed by ventriculostomy (22%), medication (12%), and others (7%). The surgery-shunt insertion segment can display 4.12% CAGR over the forecast period to generate close to USD 1,008.67 million by 2023. Factors driving segment growth include approval of shunts, efficacy of shunts in deterring the accumulation of CSF, and preference of the treatment by the elderly. On the other hand, ventriculostomy can exhibit 4.92% CAGR during the assessment period to generate close to USD 400.92 million by 2023.
• By End-user, diagnostic centers can exhibit 4.92% CAGR during the assessment period to touch a value of USD 397.28 million by 2023. Hospitals & clinics can generate USD 951.56 million by 2023 at a CAGR of 4.12% CAGR throughout the forecast period.

Regional Analysis:

Region-wise, the hydrocephalus market includes Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). Americas held close to 36% market share in 2017, followed by Europe (32%), APAC (24%), and MEA (8%).

The Americas region had dominated the market in 2017 owing to high incidence of traumatic brain injuries (TBI) and prevalence of neurovascular diseases. It can accrue close to USD 615.79 million by 2023, at a CAGR of 3.80% over the forecast period. The growth is facilitated by development of imaging technologies and shunts which can improve the surgical outcomes.

Get Access Full Report @ https://www.marketresearchfuture.com/reports/hydrocephalus-market-1719 

The APAC region can exhibit the highest CAGR of 5% during the assessment period owing to high cases of accidents which cause TBI. The latent potential of economies of China and India coupled with the large patient pool can create opportunities for equipment manufacturers to establish their units. The region can generate USD 439.36 million by 2023.

The Europe region can generate USD 555.63 million by 2023 at a CAGR of 4.61% during the forecast period. This can be attributed to improvement of hydrocephalus management, continuous development of shunts, and upskilling of neurosurgeons.